PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 9, 2025BMC Gastroenterology1 citationsOpen Access

Etiology of cirrhosis is associated with risk of hepatic decompensation and hepatocellular carcinoma

View Full Paper
MNMichelle NgOBOlgert BardhiKLKrystal Lai

Key Points

  • This research examines how the etiology of cirrhosis affects risks of hepatic decompensation and hepatocellular carcinoma (HCC).
  • Conducted a retrospective cohort study of adults with cirrhosis from two U.S. health systems.
  • Excluded patients with prior HCC or prevalent ascites and hepatic encephalopathy.
  • Utilized Fine-Gray sub-distribution hazard models to analyze time-to-incident hepatic decompensation and HCC.
  • 36.4% of patients developed incident hepatic decompensation over a median follow-up of 84.7 months.
  • 14.5% developed hepatocellular carcinoma (HCC).
  • Cumulative incidence of hepatic decompensation was 7.0%, 10.8%, and 16.3% at 1, 2, and 3 years respectively.

Abstract

Abstract Background The impact of the changing epidemiology from viral to non-viral etiologies of cirrhosis on the burden of liver-related complications remains unclear. Methods We conducted a retrospective cohort study of adult patients with cirrhosis and an index outpatient visit between January and December 2015 at two U.S. health systems. We excluded patients with a history of hepatocellular carcinoma (HCC) or both prevalent ascites and hepatic encephalopathy. Fine-Gray sub-distribution hazard models were used to characterize time-to-incident hepatic decompensation and incident HCC through 2020, with liver transplantation and death as competing events, and multivariable Fine-Gray regression was used to identify associated factors. Results We identified 1029 patients (median age 58 years, 54.9% male, 19.5% non-Hispanic White). Over a median follow-up of 84.7 months, 36.4% developed incident hepatic decompensation (46.7% ascites, 21.1% hepatic encephalopathy, and 32.3% ascites plus hepatic encephalopathy), 14.5% developed HCC, 2.0% underwent transplant, and 23.0% died. The cumulative 1-, 2-, and 3-year incidence of hepatic decompensation were 7.0%, 10.8%, and 16.3% and incidence of HCC were 3.0%, 5.0%, and 6.9%, respectively. Compared to viremic hepatitis C, higher risk of hepatic decompensation was associated with metabolic dysfunction-associated steatotic liver disease (MASLD) (sHR 1.52, 95% CI 0.94 - 2.45) and alcohol-associated cirrhosis (sHR 1.68, 95%CI 1.10 - 2.57), while incident HCC was inversely associated with MASLD (sHR 0.27; 95% CI 0.12–0.59) and alcohol-associated cirrhosis (sHR 0.45; 95% CI 0.23–0.84). Conclusion Increasing proportions of non-viral liver disease will likely lead to a greater burden of hepatic decompensation and reduced HCC in contemporary populations.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ng et al. (2025) studied this question.

synapsesocial.com/papers/69401d5b2d562116f28f8bd3https://doi.org/10.1186/s12876-025-04538-y
Ask AI
Helpful
Bookmark
Share
View Full Paper